News

Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Since January 2026, Novanta has been in a holding pattern, posting a small return of 3.3% while floating around $142.

Novanta was recently upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst optimism tied to an upward revision in earnings estimates. This earnings-driven upgrade highlights how changing expectations about Novanta's profit outlook can influence investor attention and perceived business strength over time. Next, we'll examine how the upgraded earnings outlook and analyst ranking could reshape Novanta's existing investment narrative and risk profile. Invest in the nuclear...

Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.

The deal will give Novanta entry into the minimally invasive surgery segment and is expected to bolster it position in the medical consumables space.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Novanta (NASDAQ:NOVT) and its peers.

Shareholders of Novanta Inc. ( NASDAQ:NOVT ) will be pleased this week, given that the stock price is up 14% to US$156...

Novanta (NOVT) just posted first quarter results that beat earnings and revenue expectations, with sales of US$257.71 million and forward guidance above analyst estimates, marking a shift after earlier quarters of missed forecasts. See our latest analysis for Novanta. The strong first quarter beat and improved guidance appear to be feeding into momentum, with the share price up 11.8% over the past month and a year to date share price return of 26%. This is despite the 3 year total shareholder...

Ouster (OUST) delivered earnings and revenue surprises of +19.36% and +6.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Novanta’s analyst story has shifted with a new consensus price target of US$150, up from US$138, now sitting against a model fair value that remains at US$157. This updated target reflects fresh views after Q4, where analysts are weighing potential upside against the risk that the company may not fully match the assumptions built into their revised models. Read on to see how these moving targets, and the narrative around them, can help you track the next phase of the Novanta story. Stay...